Canada's CDA-AMC backs conditional reimbursement for Yorvipath

Palopegteriparatide gains a positive reimbursement recommendation in Canada for adults with chronic hypoparathyroidism inadequately controlled on standard therapy.

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
A sterile cleanroom contains large stainless steel bioreactors with intricate piping and valves, modular processing equipment, and white double doors, all brightly illuminated by overhead lighting.

Canada's Drug Agency (CDA-AMC) has recommended conditional public reimbursement of Yorvipath (palopegteriparatide injection) for eligible adults with chronic hypoparathyroidism whose condition remains inadequately controlled on conventional calcium and active vitamin D therapy. The recommendation, announced on 3 September 2026, is a joint milestone for Pendopharm, the specialty division of Montreal-based Pharmascience Inc., and Danish rare-disease originator Ascendis Pharma.

Yorvipath is a long-acting parathyroid hormone (PTH) replacement therapy. Health Canada authorised the product on 28 January 2026, making the CDA-AMC recommendation a relatively swift follow-on step in the Canadian market access sequence. Final listing decisions will be made independently by participating federal, provincial, and territorial drug plans, meaning the path to patient access still has several procedural stages to clear.

The clinical basis

The CDA-AMC review drew on data from the Phase 3 PaTHway clinical trial, which evaluated palopegteriparatide in adults with chronic hypoparathyroidism. The release did not disclose specific trial outcomes, such as primary endpoint results or response rates, though Ascendis Pharma has previously published PaTHway data in peer-reviewed literature. The conditional nature of the recommendation suggests the agency applied criteria around patient eligibility, likely restricting reimbursement to those who have failed or cannot tolerate standard-of-care supplementation.

Aliya Khan, Clinical Professor of Medicine and Director of the Calcium Disorders Clinic at McMaster University, framed the clinical need clearly: "People living with chronic hypoparathyroidism can face significant daily challenges even while taking intensive calcium and active vitamin D therapy. For appropriate adults, a PTH replacement therapy may offer a different treatment approach by addressing the underlying hormone deficiency."

Jad Isber, Vice-President and General Manager of Pendopharm, described the recommendation as "an important milestone" and said the company would continue working through the Canadian reimbursement process.

Market and regulatory context

Chronic hypoparathyroidism is a rare endocrine disorder characterised by insufficient PTH secretion, leading to low serum calcium and elevated phosphate. Conventional management with oral calcium supplements and active vitamin D analogues controls symptoms in many patients but leaves a meaningful subset with persistent hypocalcaemia and associated complications including neuromuscular symptoms and renal impairment.

Palopegteriparatide competes in a small but growing field of PTH-axis therapies for hypoparathyroidism. Natpara (parathyroid hormone 1-84, from Takeda) has been available in some markets but faced manufacturing-related supply disruptions, creating a gap that newer entrants have sought to fill. Ascendis Pharma's TransCon technology, which underpins palopegteriparatide's extended pharmacokinetic profile, is the same platform the company applies across its endocrinology pipeline, including candidates in growth hormone deficiency and achondroplasia.

For Pendopharm, securing reimbursement access across Canada's provincial formularies will be the near-term commercial priority. The conditional framing of the CDA-AMC recommendation means payers may apply managed-entry criteria, specialist prescribing requirements, or outcomes-based conditions. Similar conditional recommendations from CDA-AMC have historically taken several months to translate into provincial listing decisions, so commercial uptake is unlikely to be immediate.

Patient advocates have welcomed the development. Patty Keating, Executive Director of the HypoPARAthyroidism Association (USA), said the recommendation "recognises the challenges experienced by some people living with chronic hypoparathyroidism and the need for access discussions for eligible patients." The involvement of a US-based patient group in a Canadian regulatory announcement is notable, reflecting the small global patient community for this indication and the cross-border nature of rare-disease advocacy.

Sector

Topic

Geography